Scholarlink

<p>NanoCubes loaded film-forming spray (NanoCuboSpray) is a new formulation that can be explored for nanoscale drug delivery. In the present work, epigallocatechin 3-gallate (EGCG) was encapsulated into NanoCuboSpray (NCS) for oral submucous fibrosis (OSF) treatment. The newly formulated EGCG NCS is then evaluated for <i>ex vivo</i> permeation, drug retention, <i>in vivo</i> efficacy, and safety. The developed formulation was homogeneous, viscous, spreadable and mucoadhesive on the buccal mucosa. EGCG NCS had good permeation and buccal mucosal retention in the <i>ex vivo</i> studies. The NCS with 81.81&#xa0;mg/kg EGCG dose significantly enhanced mouth opening and effectively upregulated collagen and downregulated TGF-β1 in rats with areca nut extract-induced OSF. EGCG NCS demonstrated better improvements in histopathological and antioxidant parameters compared to EGCG hydrogel and betamethasone injection (BTM Inj.). In the safety evaluation, NCS treatment had negligible changes in histopathological features and serum biochemical markers, maintaining results comparable to the normal control group. Therefore, the optimized NCS presents a safer alternative strategy for treating OSF and holds the potential for further evaluation of its clinical efficacy.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nanocubospray of Epigallocatechin Gallate for Prevention of Oral Submucous Fibrosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月4日

查看全文
  • Chetan Hasmukh Mehta,
  • Varalakshmi Velagacherla,
  • Suman Manandhar,
  • Yogendra Nayak,
  • Karkala Sreedhara Ranganath Pai,
  • Shruthi Acharya,
  • Usha Yogendra Nayak

摘要

NanoCubes loaded film-forming spray (NanoCuboSpray) is a new formulation that can be explored for nanoscale drug delivery. In the present work, epigallocatechin 3-gallate (EGCG) was encapsulated into NanoCuboSpray (NCS) for oral submucous fibrosis (OSF) treatment. The newly formulated EGCG NCS is then evaluated for ex vivo permeation, drug retention, in vivo efficacy, and safety. The developed formulation was homogeneous, viscous, spreadable and mucoadhesive on the buccal mucosa. EGCG NCS had good permeation and buccal mucosal retention in the ex vivo studies. The NCS with 81.81 mg/kg EGCG dose significantly enhanced mouth opening and effectively upregulated collagen and downregulated TGF-β1 in rats with areca nut extract-induced OSF. EGCG NCS demonstrated better improvements in histopathological and antioxidant parameters compared to EGCG hydrogel and betamethasone injection (BTM Inj.). In the safety evaluation, NCS treatment had negligible changes in histopathological features and serum biochemical markers, maintaining results comparable to the normal control group. Therefore, the optimized NCS presents a safer alternative strategy for treating OSF and holds the potential for further evaluation of its clinical efficacy.

Graphical Abstract